august 24 2025 glp-1 GLP-1s: The world's first longevity drug? GLP-1 Update: Novo Nordisk Sues

Gastrointestinal issues dominate, including nausea (44-50 percent of patients), vomiting (24-31 percent), diarrhea (30-40 percent), constipation (24-30 percent), and abdominal pain (20-25 percent)

Bariatric-metabolic surgery versus conventional medical treatment in obese patients with type 2 diabetes: 5 year follow-up of an open-label, single-centre, randomised controlled trial

Q: What is the purity level of your Retatrutide

Curr Opin Hematol 9(4):294-302, 2002

Set us as preferred While the new anti-obesity medications known as GLP-1s are only one tool to combat obesity and cardiometabolic disease, they have changed the medical landscape and are clinically important in treating these diseases

What are the side effects of GLP-1